A powerful new agonist: flooding the system with growth hormone.
Niemczyk et al. treated predialysis chronic kidney disease patients with a new growth hormone-releasing hormone agonist, AKL-0707, and noted important changes in body composition characterized by an increase in fat-free mass, a modest rise in bone mineral content, and a reduction in fat mass. These changes were accompanied by a reduction in both serum urea nitrogen and normalized protein nitrogen appearance rate, while dietary protein intake was unchanged. Importantly, there were no serious adverse events.
Lim
Victoria S
VS
Division of Nephrology, Department of Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA. Victoria-lim@uiowa.edu
D001823:Body Composition; D015519:Bone Density; D017322:Clinical Trials, Phase II as Topic; D004311:Double-Blind Method; D013007:Growth Hormone-Releasing Hormone / Q000819:agonists* / Q000378:metabolism; D019382:Human Growth Hormone / Q000009:adverse effects / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism; D008954:Models, Biological; D009765:Obesity / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic
D019382:Human Growth Hormone; D013007:Growth Hormone-Releasing Hormone